Bypassing Agents Prophylaxis In Patients With Haemophilia And Inhibitors Undergoing Surgery: A Decision Analysis In Spain
نویسندگان
چکیده
منابع مشابه
Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors using Bypassing Agents in Iran
Bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. The aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in Iran. This study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inh...
متن کاملcost components of treatment protocols of haemophilia patients with inhibitors using bypassing agents in iran
bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. the aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in iran. this study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inhibitor...
متن کاملcomparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors
conclusions although differences between the two products were very close to each other, they reported similar effects on joint bleeds. further clinical studies should be performed by incorporating a standardized measurement in comparative efficacy of apcc and rfviia. results the mean of bleeding reduction in apcc and rfviia were 71.2% with ci 95% (lower limit 86.8% and upper limit 82%) and 72....
متن کاملUse of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Up to 30% of haemophilia A patients and up to 3% of haemophilia B patients develop neutralizing antibodies (inhibitors) to factor VIII or factor IX, rendering replacement therapies ineffective and making the management of bleeding episodes particularly challenging.1–3While patients with low titre inhibitors may benefit from higher doses of factors VIII or IX, patients with higher antibody level...
متن کاملComparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
CONTEXT Mild-to-moderate bleeding disorders in haemophilia are primarily treated via recombinant activated factor VII a (rFVIIa) or activated prothrombin complex concentrate (aPCC). However, the efficacy of each bypassing agents may vary and none of them is universally effective. EVIDENCE ACQUISITION After reviewing the databases of PubMed, Scopus, MD Consult, Ovid, Trip database, Google Scho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2017
ISSN: 1098-3015
DOI: 10.1016/j.jval.2017.08.863